VistaGen Therapeutics (VTGN)
(Delayed Data from NSDQ)
$3.02 USD
+0.10 (3.42%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $3.03 +0.01 (0.33%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.02 USD
+0.10 (3.42%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $3.03 +0.01 (0.33%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Zacks News
VistaGen Therapeutics (VTGN) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
VistaGen Therapeutics (VTGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy
by Zacks Equity Research
VistaGen Therapeutics (VTGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
VistaGen Therapeutics (VTGN) delivered earnings and revenue surprises of 14.63% and 72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Seer, Inc. (SEER) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Seer (SEER) delivered earnings and revenue surprises of 2.78% and 7.61%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
ADC Therapeutics (ADCT) delivered earnings and revenue surprises of 13.64% and 8.63%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Does VistaGen Therapeutics, Inc. (VTGN) Have the Potential to Rally 160% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for VistaGen Therapeutics, Inc. (VTGN) points to a 160% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Immunocore Holdings PLC Sponsored ADR (IMCR) Moves 6.9% Higher: Will This Strength Last?
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
How Vistagen (VTGN) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Vistagen (VTGN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More News
by Zacks Equity Research
Regulatory updates from SAGE and Galera (GRTX) are in focus in the biotech sector.
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 16.67% and 41.94%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
BioCryst (BCRX) Down as it Discontinues Developing PNH Drug
by Zacks Equity Research
BioCryst (BCRX) down as it drops the development of BCX9930, which was being evaluated for PNH.
Cytokinetics (CYTK) Up Despite Unfavorable FDA Committee Voting
by Zacks Equity Research
Cytokinetics (CYTK) gets an unfavorable recommendation from CRDAC on omecamtiv mecarbil for the treatment of heart failure with reduced ejection fraction.
What Makes VistaGen Therapeutics, Inc. (VTGN) a New Buy Stock
by Zacks Equity Research
VistaGen Therapeutics, Inc. (VTGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 0% and 388.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Adma Biologics (ADMA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adma Biologics (ADMA) delivered earnings and revenue surprises of 22.22% and 8.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 5.56% and 26.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
VistaGen Therapeutics, Inc. (VTGN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of -33.33% and 88.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Nurix Therapeutics, Inc. (NRIX) Soars 14.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Nurix Therapeutics, Inc. (NRIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Bristol Myers' (BMY) Opdivo Data Positive for Neoadjuvant NSCLC
by Zacks Equity Research
Bristol Myers (BMY) posts favorable data from a late-stage study that shows neoadjuvant Opdivo with chemotherapy to significantly better the event-free survival rate in patients with resectable NSCLC.
Gilead (GILD) Magrolimab Studies' Partial Clinical Hold Removed
by Zacks Equity Research
Gilead (GILD) studies evaluating its investigational agent magrolimab in combination with Vidaza are no longer under FDAs partial clinical hold.
Novartis (NVS) Anti-PD-1 Drug Validated by EMA for Lung Cancer
by Zacks Equity Research
Novartis (NVS) application seeking approval of tislelizumab in multiple non-small cell lung cancer and esophageal squamous cell carcinoma indications gets EMA's validation.
Bristol Myers (BMY) Gets EC Nod for Opdivo's Label Expansion
by Zacks Equity Research
Bristol Myers (BMY) receives EC approval for label expansion of Opdivo for ESCC and urothelial carcinoma.
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 37.50% and 8.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: VistaGen Therapeutics, Inc. (VTGN) Q3 Earnings Expected to Decline
by Zacks Equity Research
VistaGen Therapeutics, Inc. (VTGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of -40.00% and 9.48%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?